The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.
Vaccines, Blood & Biologics
From: Pracht, Leigh
Sent: Monday, April 22, 2013 11:05 AM
Subject: STN 125466/0 Information Request
Our Reference: BL 125466/0
Novo Nordisk Inc.
Attention: Lewis Pollack, PhD
April 22, 2013
Sent by email
Dear Dr. Pollack:
We are reviewing your October 15, 2012 biologics license application (BLA) for Antihemophilic Factor (Recombinant), Plasma/Albumin Free [NovoEight]. We determined that the following information is necessary to continue our review:
1. Please ship additional NovoEight material, as specified below, to complete the in-support testing.
--(b)(4)--- 250 IU/vial two (2) vials
--(b)(4)--- 250 IU/vial five (5) vials
--(b)(4)--- 1000 IU/vial two (2) vials
--(b)(4)--- 2000 IU/vial three (3) vials
--(b)(4)--- 3000 IU/vial three (3) vials
Please ship the material to the address below:
Division of Biological Standards and Quality Control (DBSQC)
NLRC, Bldg. B, Rm. 2410
5516 Nicholson Lane, Kensington, MD 20895
The review of this submission is on-going and issues may be added, expanded upon, or modified as we continue to review this submission.
Please submit your response to this information request as an amendment to this file by May 10, 2013 referencing the date of this request. If you anticipate you will not be able to respond by this date, please contact the Agency immediately so a new response date can be identified.
The action due date for this file is October 15, 2013.
If you have any questions, please contact me at (301) 827-6116.
Leigh A. Pracht
Regulatory Project Manager
WOC1; RM562N; HFM-380
1401 Rockville Pike
Rockville, MD 20852
Fax: 301- 827-2857
THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender by e-mail or phone.